Pathology: endometrial cancer; endometrial cancer - (neo)adjuvant (NA);
| endometrial cancer | endometrial cancer - (neo)adjuvant (NA) | |||||||||||
| AtTEnd, 2023 | MITO END-3, 2023 | RUBY (part 1), 2023 | RUBY (part 2), 2024 | DUO-E (durvalumab follow by durvalumab and olaparib vs control arms) DUPLICATE, 2023 | DUO-E (durvalumab then durvalumab alone vs control arms), 2023 | LEAP-001/ENGOT-en9, 2024 | KEYNOTE-775, 2023 | NRG-GY018_dMMR, 2023 | NRG-GY018_pMMR, 2023 | KEYNOTE-B21, 2024 | ||
| pembrolizumab plus SoC | 3 | T1 | T1 | T1 | ||||||||
| dostarlimab plus soC | 2 | T1 | T1 | |||||||||
| pembrolizumab plus lenvatinib | 2 | T1 | T1 | |||||||||
| atezolizumab plus SoC | 1 | T1 | ||||||||||
| avelumab plus SoC | 1 | T1 | ||||||||||
| durvalumab plus olaparib plus SoC | 1 | T1 | ||||||||||
| durvalumab plus SoC | 1 | T1 | ||||||||||
| placebo plus SoC | 0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 | |||
| Standard of Care (SoC) | 0 | T0 | T0 | T0 | ||||||||